A16z’s 0M biotech fund backs liquid biopsy upstart Freenome

Andreessen Horowitz’s recently-founded $200 million biotech fund has led an investment in software-enabled liquid biopsy upstart Freenome. The money will allow Freenome to hire software engineers and machine learning experts to help it bring its cancer test to market. Palo Alto, CA-based Freenome tapped a clutch of big-name investors for the $5.5 million. Andreessen Horowitz, the storied West Coast investor also known as a16z, used its months-old biotech-focused fund to lead the round. Founders Fund, Data Collective Venture Capital and Third Kind Venture Capital–which list Stemcentrx, Ginkgo Bioworks and PillPack in their healthcare portfolios–also put money into the round. The tech-skewed investor list is a reflection of what Freenome sees as being unique about it in the increasingly-congested blood testing startup sector. “The novel aspect of our technology, and what…


Link to Full Article: A16z’s 0M biotech fund backs liquid biopsy upstart Freenome